Financial Data and Key Metrics Changes - OPKO Health reported total revenues for Q4 2025 of $148.5 million, a decrease from $183.6 million in Q4 2024, primarily due to the Labcorp transaction [28] - The net loss for Q4 2025 was $31.3 million, or $0.04 per share, compared to a net income of $14 million, or $0.01 per diluted share in Q4 2024 [29] - The company ended the quarter with $369 million in cash and cash equivalents, which is sufficient to fund ongoing operations and development plans [21] Business Line Data and Key Metrics Changes - Revenue from the diagnostics business in Q4 2025 was $71.1 million, including $7 million from the 4Kscore test, which grew by over 16% compared to $6 million in Q4 2024 [22] - Revenue from the pharmaceutical segment was $77.4 million in Q4 2025, compared to $80.5 million in the prior year, with product sales increasing to $43.7 million from $37.4 million [24] - The diagnostics operating loss was $18.3 million, an improvement from $21.7 million in Q4 2024 [24] Market Data and Key Metrics Changes - Global pharmaceutical product sales grew by 17% year-over-year in 2025 [18] - The 4Kscore test volume increased by more than 6% year-over-year, with expectations for continued growth as payer coverage expands [19] Company Strategy and Development Direction - OPKO aims to position its diagnostics business for profitability, advance its ModeX pipeline, and strengthen its balance sheet through strategic partnerships and asset sales [4] - The company has streamlined its operations by divesting its oncology division, allowing a focus on core clinical laboratory services and the 4Kscore test [5] - ModeX is a central component of OPKO's long-term strategy, with multiple clinical-stage programs and collaborations with Merck and Regeneron [6][12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about 2026, citing multiple value-creating catalysts and a strong cash position to support R&D investments [7] - The company expects total revenue for Q1 2026 to be between $125 million and $140 million, with pharmaceutical product revenue projected at $38 million to $45 million [30] - For the full year 2026, total revenue is expected to be between $530 million and $560 million, with a focus on expanding R&D investments [31] Other Important Information - OPKO repurchased over $90 million in common shares and convertible notes in 2025, demonstrating a commitment to returning capital to shareholders [7] - The company received $28.5 million in non-dilutive funding from BARDA for its COVID-19 and influenza antibody programs [15] Q&A Session Summary Question: Timing of potential data disclosure for MDX-2001 - Management indicated that results from the phase I-A trial will be announced at an upcoming conference, with expectations for data by the end of 2026 [37] Question: Drivers of profit share increase for NGENLA - The increase in profit share was attributed to Pfizer's growth and market share gains, with guidance for 2026 set at $34 million to $37 million [39] Question: Growth in the 4K diagnostic test segment - The 6% growth in the 4Kscore test was primarily driven by urology field efforts, with expectations for continued growth as payer coverage improves [44] Question: Studies for the EBV vaccine moving to phase II - Ongoing studies aim to gather more data on EBV naive patients, with expectations for phase II trials to start next year [50] Question: Status of the GLP-1 glucagon combo asset - The GLP-1 glucagon program is in the final stages of IND submission, with plans to enter phase I trials once cleared [57]

Core Insights - The FDA has cleared Abpro's Investigational New Drug (IND) application for ABP-102 / CT-P72, enabling the initiation of the first clinical-stage solid tumor program [1][2] - The Phase 1 clinical trial is set to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABP-102 / CT-P72 in patients with HER2-positive solid tumors, with Celltrion leading the study [2][7] Group 1: Clinical Development - The Phase 1 clinical trial is anticipated to commence in the first half of 2026, following final site activation and regulatory processes [7] - The study will include dose-escalation and dose-expansion cohorts to inform future clinical development strategies [7] Group 2: Product Details - ABP-102 / CT-P72 is a multispecific HER2 × CD3 T-cell engager designed to selectively target HER2-overexpressing tumor cells while engaging cytotoxic T cells, aiming to enhance tumor selectivity and limit activity in normal HER2-low tissues [3][4] - Preclinical studies demonstrated robust antitumor activity in HER2-high tumor models, with selective efficacy for HER2-high tumors [4][6] Group 3: Safety and Efficacy - The optimized CD3 binding of ABP-102 / CT-P72 is intended to mitigate excessive immune activation and reduce the risk of cytokine release syndrome, with non-human primate studies showing it was well tolerated at doses up to 80 mg/kg [5] - Additional preclinical evaluations indicated activity in tumor models representing resistance to existing HER2-directed therapies, highlighting its potential to address unmet medical needs [6] Group 4: Company Background - Abpro is focused on developing next-generation antibody therapies for severe diseases, including HER2+ cancers and other conditions, utilizing its proprietary DiversImmune® platform [8] - Celltrion, based in South Korea, specializes in developing innovative therapeutics and aims to improve patient access to reliable healthcare [11]